Monday, May 21, 2018
Company News: Page (1) of 1 - 04/25/18 Email this story to a friend. email article Print this page (Article printing at page facebook
Samsung BioLogics becomes the first in the South Korean pharma industry to achieve ISO 22301 Certificate
(April 25, 2018)

INCHEON, South Korea, April 25, 2018 /PRNewswire/ -- Samsung BioLogics, one of the global biologics development and manufacturing companies, announced today that it received ISO 22301 certificate, the international standard Business Continuity Management System (BCMS), from BSI (British Standards Institution), a global certification association. They are the first South Korean company to do so.

Tae Han Kim, CEO of Samsung BioLogics, is receiving ISO certificate from Jongho Lee, CEO of BSI Korea.

ISO 22301 certificate is a comprehensive standard published by the International Organization for Standardization (ISO) that represents the highest level of commitment to business continuity and disaster preparedness.

In the case of biopharmaceuticals, the production and supply of biologics is directly linked to the life of patients suffering from serious diseases including cancer, so it is crucial to stably produce biologics and deliver them accurately.

Accordingly, global pharmaceutical companies consider crisis systems critical and request a high level of crisis response system from their partners.

Samsung BioLogics launched an internal task force composed of 16 teams and 22 people and discovered a total of 573 projected risks over about two years, reflecting global customer' needs.

Ultimately, Samsung BioLogics established an emergency response scenario by anticipating an internal or external crisis that may happen, which led to the attainment of ISO certification.

Furthermore, Samsung has also proved that it is able to maintain the continuity of management in a short period of time in case of an unexpected emergency such as a natural disaster, by pre-setting and preparing resources and time required to overcome the crisis.

"Through ISO 22301 certificate, Samsung's quality management ability will be recognized once again and it will be a great help in order to get additional orders," said TH Kim, CEO of Samsung BioLogics. "Samsung will continue to identify internal and external risks and improve our processes so that we will become a company that leads global standards for crisis response by providing our customers with high service availability and business continuity."

About Samsung BioLogics

Samsung BioLogics is a global full-service provider of quality-driven contract process development and cGMP manufacturing to the global biopharmaceutical industry. Our facilities are custom designed for monoclonal & recombinant production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services, clinical and commercial bulk cGMP manufacturing of drug substance and drug product including quality assurance, quality control, regulatory compliance standards & support for our customers. For additional information about the company, please visit

Media Enquiries:

Inchan Hwang
[email protected]

Dahyun Ahn
[email protected]

Cision View original content with multimedia:

SOURCE Samsung Biologics

Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords:Korea,Science,Medical,Cancer,Business,disaster,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
  • Regenerative Medicine Market Analysis Study Found Huge Boom By Rising Prevalence Of Chronic Diseases And Genetic Disorders Till 2025: Grand View Research,Inc.
  • Global Molecular Diagnostics Markets, 2016-2024 - Focus on Infectious Disease Testing, Blood Screening, Cancer Screening & Other Applications
  • Global Sleep Apnea Diagnostic and Therapeutic Devices Strategic Business Report 2018
  • Global Sleep Apnea Diagnostic and Therapeutic Devices: 2016/18-2024 Strategic Business Analysis & Forecast Report - mHealth-Enabled Sleep Tracking Devices Gain Ground

  • Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.
  • Altogen Labs xenograft services for drug development studies of anti-cancer therapeutics
  • HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage
  • Dr. Haydee Gonzalez Hidalgo joins The Oncology Institute of Hope and Innovation
  • eClinical Solutions Market Size Is Projected To Reach $13 Billion By 2024

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines